Manufacturing, Cell Therapies

Novartis’ AveXis to Invest $55 Million in New Gene Therapy Manufacturing Facility

May 25, 2018

The gene therapy company is expected to invest $55 million in a new manufacturing facility that will produce therapies for rare neurological genetic diseases.

FUJIFILM Adds Late-Phase and Commercial Fill/Finish Capabilities

May 24, 2018

In adding a Vanrx Pharmasystems aseptic filling isolator, FUJIFILM adds fill/finish for gene therapies and viral vaccines.

Gilead’s Kite Expands Cell Therapy Facilities in US, Europe

May 22, 2018

The company has leased and purchased facilities in the United States and Europe to expand its cell therapy pipeline.

Lonza to Invest in Mid-Scale Biologics, Cell Therapy Manufacturing

May 07, 2018

Lonza announces addition of mid-scale biologics manufacturing capacity and cell-therapy suites at Portsmouth, NH site.

New Processing System Streamlines Cell Therapy Manufacturing

May 04, 2018

GE Healthcare’s new Sefia S-2000 cell processing system allows operators to conduct multiple cell therapy manufacturing steps with one instrument.

GE Speeds Up Production of Viral Vector-Based Therapeutics

April 17, 2018

The company is launching a new pre-fabricated, ready-to-run manufacturing facility that is expected to significantly decrease the production timeline for viral vector-based therapeutics.

Lonza Opens Dedicated Cell and Gene Therapy Manufacturing Facility

April 10, 2018

The new 300,000-square-foot facility is considered the largest dedicated cell and gene therapy manufacturing facility with fully integrated services.

Lilly, Sigilon Partner on Encapsulated Cell Therapies for Diabetes

April 09, 2018

Under this global collaboration, the companies will develop encapsulated cell therapies for treating Type 1 diabetes.

Hitachi to Manufacture Regenerative Medicines

March 26, 2018

Hitachi will manufacture regenerative medicines developed by Daiichi Sankyo and SanBio Group.

Cesca Licenses CAR-T Cellular Processing Services to China’s Boyalife Group

March 26, 2018

The agreement gives IncoCell Tianjin, a wholly-owned subsidiary of China-based Boyalife Group, access to Cesca’s celluar processing contract development and manufacturing services.